Spectranetics (SPNC) Target, Estimates Cut at Needham & Company; Stumble Creates Buying Chance
Get Alerts SPNC Hot Sheet
Rating Summary:
5 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Needham & Company analyst Mike Matson lowered estimates and its price target on Spectranetics (NASDAQ: SPNC) from $35 to $30 after the company guideed Q1 and FY 2014 lower. The firm, however, maintained a Buy rating saying the lead management stumble creates a buying opportunity.
Matson comments, "SPNC pre-announced a revenue miss for 1Q14 and lowered its 2014 guidance given weaker than expected Lead Management sales. While this is disappointing and likely to lead to additional selling pressure, we maintain our Buy rating since we believe that the issues are ultimately transitory in nature, and we expect revenue growth to recover given SPNC's sales force expansion, mechanical lead removal tools launch, and upcoming in-stent restenosis (ISR) approval. In particular, we expect the ISR approval to serve as a significant catalyst later this year. We have lowered our price target to $30 from $35 due to our estimate reduction and peer multiple compression."
The firm cut FY 2014 EPS from ($0.20) to ($0.07) and FY 2015 EPS from $0.14 to $0.13.
For an analyst ratings summary and ratings history on Spectranetics click here. For more ratings news on Spectranetics click here.
Shares of Spectranetics closed at $26.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- Dollar General (DG) PT Raised to $175 at Argus
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!